Risk factor
Low price volatility
Profitability factor
Somewhat favourable analyst view
About
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management,...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of GLAND.NS is 2127 and suggests 28% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
Buy
Sell